Mr Thomas has been a Director since 15 December 2011 and was appointed Chairman of the Company on 16 November 2012. Mr Thomas had more than 35 years’ experience in the securities industry. He is currently a Director of Biotron Limited. He is Chairman of Grahger Retail Securities. Mr Thomas was an Independent Director of Virgin Australia Limited from September 2006 to February 2018. He is a former Director of REVA Medical Limited a US medical device company.
Mr Thomas has been a Non-Executive Director of Starpharma since 4 December 2013 and was appointed Chairman of Starpharma on 13 June 2014. Between October 1999 and September 2008 Mr Thomas had several roles within Citigroup Corporate and Investment Bank Australia and New Zealand including Chief Executive Officer, Chairman and Consultant.
He is a former Director and Non-Executive Chairman of HeartWare Limited, subsequently HeartWare International, also a US medical device company.
Mr Thomas is a Fellow of the Institute of Company Directors (FAICD) , Stockbrokers and Financial Advisers Association Limited (SAFAA),Financial Services Institute of Australia ( FINSIA) and the Royal Society of New South Wales (FRSN) and he is also a Director of O'Connell Street Associates, and Co-Chair of the State Library of NSW Foundation.
Mr Bartels was appointed as a Non-Executive Director and Chairman of Aus Bio Limited on 11 February 2005. He retired from the Chair on 16 November 2012 and remains a Non-Executive Director. Mr Bartels was Chairman of the ASX-listed Starpharma Holdings Limited from 6 August 2003 until his retirement from the Chair and the Board on 13 June 2014. Mr Bartels was Chairman of the Dean’s External Advisory Committee for the Faculty of Medicine, Dentistry and Health Science at the University of Melbourne 2012/2016. He is the immediate past Chairman of the Australian Sports Commission, the Australian Institute of Sport and the Commonwealth Heads of Government Committee for Sport and the Royal Women’s and Children’s Hospitals and was a Director of the Melbourne Business School (Melbourne University) and a member of the Business Council of Australia for eight years. Mr Bartels was previously CEO and Managing Director of Coles Myer Limited and before that CEO and Managing Director of Fosters Brewing Company Limited. He has had broad-based experience in the pharmaceutical industry with previous roles with DHA Pharmaceuticals and Abbott Laboratories. Mr Bartels is Patron and life member of the Australian Cycling Federation.
Mr Farquharson has been a Director since the date of incorporation of the company on 3 March 2000. Mr Farquharson has been involved in stockbroking for over 50 years. In 1970, he joined the partnership of A.C. Goode & Co. and became a member of the Australian Stock Exchange. More recently, he was Vice President of Merrill Lynch Private (Australia) and a Senior Investment advisor at Morgans Financial Limited until his retirement from stockbroking on 30 June 2017. He has had many years’ experience dealing with “small to mid-cap” companies including equity raisings and management issues.
Dr Jenkins has been a Director since the date of incorporation of the Company on 3 March 2000. Dr Jenkins is a consultant physician and gastroenterologist and has held or holds both clinical research positions within the Alfred Hospital and also the Baker Medical Research Institute, Melbourne. He has held the positions of Head, Clinical Business Unit Gastroenterology and Gastrointestinal Surgery and Clinical Dean at the Alfred Hospital for the Monash University Faculty of Medicine. He is also a past Chairman of the Committee of Chairman Senior Medical Staffs of Major Victorian Hospitals. Dr Jenkins has been a Director of a number of private and public biotechnology companies, including the ASX listed Starpharma Limited where he was Deputy Chairman before his retirement (in 2015) after 17 years as a Director. He is a former Director and Chairman of Immuron (formerly Anadis Limited). Dr Jenkins is a former judge of the Australian Technology Awards. He is experienced in the issues and problems that face early stage biomedical research and development companies in Australia.
Dr Wu was appointed as a Director on 3 September 2001. Following university graduation, Dr Wu worked as a research scientist at the Institute of Antibiotics in Shanghai, during which time he was involved in the discovery and design of new antibiotics including Rifampicin, Piperacillin and the Cephalosporins. Dr Wu came to Australia in the early 1980s. He completed his PhD at Latrobe University and worked as a postdoctoral fellow in Natural Product Chemistry at Australian National University. In the late 1980s, Dr Wu joined the anti-influenza research group at Victorian College of Pharmacy and had direct involvement in the design and was instrumental in the eventual synthesis of the Glaxo Wellcome anti-influenza compound now known worldwide as Relenza. From 1995 to 2001, Dr Wu was the Senior Principal Research Fellow at Biota Holdings Limited. He was awarded the Biota prize in 1997 and received the Clunies Ross National Science and Technology Award for his contribution to Australian science in 2000. Dr Wu’s research interests include drug design and synthesis, natural product chemistry and the development of new antibiotics and other chemo-therapeutic agents.